An observational cohort study to determine effective treatment strategy in routine care in patients with psoriatic arthritis using data from four Nordic Biologics Registries
Latest Information Update: 27 Jun 2022
At a glance
- Drugs Abatacept (Primary) ; Apremilast (Primary) ; Baricitinib (Primary) ; Ixekizumab (Primary) ; Secukinumab (Primary) ; Tofacitinib (Primary) ; Upadacitinib (Primary) ; Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
Most Recent Events
- 27 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism